摘要
目的探讨利培酮联合胞磷胆碱治疗老年期精神分裂症对的疗效与不良反应。方法选择80例精神分裂症患者并分为两组各40例。联合用药组给予利培酮合并胞磷胆碱口服,单一用药组给予利培酮口服。于治疗前、治疗后第2、4、8周进行阳性和阴性症状量表(PANSS)、临床记忆量表(CMS)、临床痴呆评定量表(CDR)、不良反应量表(TESS)评定。结果治疗8周后,两组的PANSS总分均较治疗前有下降(P<0.05),两组疗效之间无统计学差异(P>0.05);联合用药组在CMS、CDR的改善较单一用药组明显(P<0.05);联合用药组不良反应较单一用药组少(P<0.05)。结论利培酮合并胞磷胆碱治疗老年期精神分裂症疗效好,能减少锥体外系副反应的发生,更好地改善老年期精神分裂症患者的认知功能。
Objective To investigate the clinical efficacy and safety of Risperidone combined with Citicoline in the treatment of senile schizophrenia. Methods 80 patients with schizophrenia were randomly divided into two groups. The combination group was treated by Risperidone combined Citicoline for 8 weeks, while single-drug group was treated by Risperidone for same period. The positive and negative symptom scale （PANSS）, clinical memory scale （CMS）, clinical dementia rating （CDR）, treatment emergent symptoms scale （TESS） were used to measure therapeutic efficacy and side effects before and at the end of 2, 4, 8 weeks of treatment respectively. Results The PANSS scores of two groups decreased significantly after the treatment （P 〈0.05）. The difference of PANSS score between two groups was not statistically significant （P〉0.05）. The difference of ADL, CDR score between two groups was statistically significant （P〈0.05）. The combination group had lower incidence of adverse reaction than the single-drug group （P 〈0.05）. Conclusions The efficacy of Risperidone combined with Citicoline in the treatment of senile schizophrenia has good clinical effect, which can reduce the incidence of EPS, and improve the cognitive function of senile patients with schizophrenia.
出处
《临床医学工程》
2013年第8期973-974,共2页
Clinical Medicine & Engineering
